Imugene (IMU) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Imugene Limited Announces Quotation of New Securities on ASXApril 14, 2025 | tipranks.comWednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025March 19, 2025 | msn.comGuess which ASX stock is surging 11% on big US FDA newsMarch 18, 2025 | msn.comImugene’s Azer-cel Receives FDA Fast Track Designation for DLBCLMarch 18, 2025 | tipranks.comImugene Limited Reports Progress in Cancer TherapiesMarch 10, 2025 | tipranks.comImugene Appoints Darren Keamy as CFO and Company SecretaryMarch 3, 2025 | tipranks.comImugene secures CD19 oncolytic virus patent in ChinaFebruary 26, 2025 | au.investing.comImugene secures patent protection in India for CF33 oncolytic virotherapy technologyFebruary 26, 2025 | au.investing.comImugene Secures Indian Patent for CF33 Oncolytic VirotherapyFebruary 26, 2025 | tipranks.comImugene Expands Capital with New Securities QuotationFebruary 21, 2025 | tipranks.comImugene Limited Issues Unquoted Equity Securities to Boost GrowthFebruary 21, 2025 | tipranks.comImugene Limited Announces Change in Director’s InterestFebruary 21, 2025 | tipranks.comBiocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapyFebruary 18, 2025 | msn.comASX Market Update: IT stocks lead Aussie bourse higher | Feb 14, 2025February 14, 2025 | msn.comImugene’s Azer-cel therapy achieves two more complete responses in patients with B-cell lymphoma blood cancerFebruary 13, 2025 | au.investing.comImugene’s Azer-cel Shows Promising Results in CAR-T Phase 1b TrialFebruary 13, 2025 | tipranks.comImugene Limited Announces Quotation of New Securities on ASXJanuary 29, 2025 | tipranks.comImugene Limited Adjusts Securities Portfolio with Cessation of Restricted Stock UnitsJanuary 29, 2025 | tipranks.comImugene Secures A$20 Million to Advance Clinical TrialsJanuary 28, 2025 | tipranks.comImugene Limited Issues Convertible Notes and Warrants to Fund Cancer Immunotherapy EffortsJanuary 27, 2025 | tipranks.comImugene Secures $46 Million Investment to Boost Clinical TrialsJanuary 24, 2025 | tipranks.comImugene Releases Shares from Voluntary EscrowJanuary 24, 2025 | tipranks.comImugene Limited Issues Unquoted Equity Securities for Employee IncentiveJanuary 24, 2025 | tipranks.comImugene Limited Successfully Passes All Resolutions at Extraordinary General MeetingJanuary 21, 2025 | tipranks.com3 ASX All Ords shares leading the charge in 2025January 10, 2025 | msn.comImugene Limited Announces New Securities Quotation on ASXJanuary 10, 2025 | tipranks.comImugene Secures $11.7m R&D Tax Refund to Boost Cancer Therapy DevelopmentJanuary 9, 2025 | tipranks.comImugene doses first Australian subject in trial of B-cell lymphoma drug candidateJanuary 3, 2025 | msn.comWhy Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higherJanuary 3, 2025 | msn.comFirst Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma careJanuary 3, 2025 | msn.comImugene doses first Australian patient in Phase 1b azer-cel clinical trialJanuary 2, 2025 | au.investing.comImugene’s Australian Trial for Innovative Cancer Therapy BeginsJanuary 2, 2025 | tipranks.comASX Penny Stocks To Watch In January 2025January 1, 2025 | finance.yahoo.comImugene Secures A$46 Million for Clinical TrialsDecember 23, 2024 | markets.businessinsider.comImugene’s Azer-cel to be Featured at Major ConferenceDecember 19, 2024 | tipranks.comImugene Limited Secures $11 Million R&D Tax RefundDecember 18, 2024 | tipranks.com6 ASX shares down 50%+ in 2024. Are they cheap?December 3, 2024 | msn.comImugene Limited Updates and Focus on Cancer TherapiesNovember 21, 2024 | markets.businessinsider.comImugene Limited Announces Director Change and Stock HoldingsNovember 21, 2024 | markets.businessinsider.comImugene Limited: Leading Innovation in Cancer TreatmentNovember 14, 2024 | markets.businessinsider.comImugene Limited Advances Amidst AGM Vote ChallengesNovember 14, 2024 | markets.businessinsider.comASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024November 11, 2024 | msn.comImugene stocks well placed to grow with clinical progress on azer-cel CAR T-cell therapy and strong cash position, say analystsNovember 11, 2024 | au.investing.comImugene Limited Begins Innovative Cancer TrialNovember 11, 2024 | markets.businessinsider.comImugene Launches Phase 1b Trial in AustraliaNovember 8, 2024 | markets.businessinsider.comImugene kicks off Australian trial for blood cancer treatmentNovember 8, 2024 | msn.comROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsightNovember 6, 2024 | finance.yahoo.comImugene Achieves Milestone in Cancer Treatment TrialNovember 5, 2024 | markets.businessinsider.comWhy Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higherNovember 5, 2024 | msn.comThe Woolworths share price just hit a 52-week low: Is it a buy?November 3, 2024 | msn.com Get Imugene News Delivered to You Automatically Sign up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Email Address IMU Media Mentions By Week IMU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMU News Sentiment▼0.001.03▲Average Medical News Sentiment IMU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMU Articles This Week▼01▲IMU Articles Average Week Get Imugene News Delivered to You Automatically Sign up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Syndax Pharmaceuticals News Amphastar Pharmaceuticals News Aurinia Pharmaceuticals News Iovance Biotherapeutics News Wave Life Sciences News 89bio News Mineralys Therapeutics News Spyre Therapeutics News Enliven Therapeutics News Arcus Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:IMU) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imugene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
